Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corp on July 27, 2021. The report addresses the termination of a material definitive agreement regarding the company's equity financing arrangements.
Key Financial Metrics
The filing does not provide current period revenue, profit, cash flow, margins, debt, or liquidity metrics. However, it discloses historical data related to the terminated sales agreement:
- Total Shares Sold: 4,301,869 shares of Common Stock.
- Average Selling Price: $6.53 per share.
- Net Proceeds Generated: Approximately $27.2 million.
- Commission Rate Paid to Banks: 3.0% of aggregate gross proceeds.
Material Changes
The primary material change reported is the termination of the Open Market Sale Agreement (SM) dated July 9, 2019, with Jefferies LLC and B. Riley FBR, Inc. The company delivered written notice of termination on July 27, 2021, and the agreement is scheduled to terminate on August 3, 2021. This action was taken in anticipation of the effectiveness of a new shelf registration statement on Form S-3.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the agreement termination. The termination is stated to occur without liability to any party, except for certain provisions that remain in full force and effect.
Investor Verification Checklist
- Verify the status and effectiveness of the new Form S-3 shelf registration statement (File No. 333-257910).
- Confirm the exact date of termination (August 3, 2021) and review the specific provisions of the Sales Agreement that remain in effect post-termination.
- Review the company's subsequent capital raising activities under the new shelf registration.